BioNTech Bets Its Balance Sheet on Oncology as Plant Closures and a New Auditor Reshape the Story
Published on 09/30/2026 at 12:50 | Editorial boerse-global.de
BioNTech is dismantling the manufacturing footprint it built during the pandemic, and the Mainz-based biotech has now confirmed that no buyer could be found for three German production sites. The facilities in Tübingen, Marburg and Idar-Oberstein will be wound down in stages through the end of 2028, a decision that touches roughly 1,800 employees and marks the sharpest break yet with the company's vaccine-era identity.
Tübingen is slated to halt production at the end of 2027, followed by Marburg in early 2028 and Idar-Oberstein at the end of that year. BioNTech picked up the sites in part through its acquisition of CureVac at the end of 2025. A severance package is being prepared that is expected to exceed the sector's customary rule of thumb of half a month's salary per year of service, with additional bonuses for families with children.
Local Pushback Meets a Strategic Rationale
Management has argued that unfavorable market and investment conditions scuppered any sale. That explanation has not gone down quietly in Tübingen, where mayor Boris Palmer said the city has three expressions of interest in hand and pressed for further efforts to save the jobs. CureVac founder Ingmar Hoerr weighed in as well, cautioning that the closures could weaken Germany's production capacity for future health emergencies.
The retreat from in-house manufacturing follows a deliberate strategic line rather than a sudden reversal. Back in May, BioNTech agreed to shift German coronavirus vaccine production to its US partner Pfizer. Shuttering the three sites is intended to free up around EUR 500 million in annual savings from 2029, money the company plans to channel straight into clinical development of cancer therapies. The financial backdrop is demanding: BioNTech reported a net loss of EUR 1.35 billion for the first half of 2026, weighed down by falling vaccine revenues and heavy research spending.
Should investors sell immediately? Or is it worth buying BioNTech?
A Leadership Handover and a Fresh Auditor
Change is coming at the very top as well. Co-founders U?ur ?ahin and Özlem Türeci intend to step away by the end of 2026 to build Arife, a new company based in Mainz. Guido Oelkers is set to take over as chief executive before February 1, 2027, with a mandate to turn cancer assets such as BNT327 and Gotistobart into a profitable business by 2030.
Governance is shifting in parallel. On September 18, the supervisory board approved the appointment of KPMG AG Wirtschaftsprüfungsgesellschaft as independent auditor for the fiscal year ending December 31, 2027. The move, which still requires shareholder approval at the upcoming annual general meeting, followed a unanimous recommendation from the audit committee after a competitive tender process. BioNTech is making the switch voluntarily under its internal corporate governance framework, as the company is not subject to any statutory auditor rotation requirement.
Where the Bull and Bear Cases Collide
For all the administrative tidying, the valuation debate ultimately rests on the clinic. Updated Phase 3 data on Gotistobart, released roughly two weeks ago, brought relief to the market and lifted the shares 3.8%. If those results hold up in further analyses, the antibody candidate could become a cornerstone of a future re-rating. The stock is trading above its 200-day moving average of EUR 84.46, and holding that level would technically open the door to a gradual recovery.
The bearish counterweight is substantial. The discontinuation of the Cevumeran colon cancer trial about three weeks ago illustrated just how unpredictable oncology research can be, and the loss of such a hopeful asset leaves a visible gap in the pipeline. Further setbacks in late-stage projects would hit the strategic pivot hard. Adding to the unease are share sales by ?ahin, a move market watchers routinely read with caution; combined with halted studies, insider selling can dampen institutional confidence.
The Levels That Matter From Here
The stock closed Tuesday at EUR 86.85, and the coming months set up a clear technical fork. As long as the shares defend the EUR 84.46 area around the 200-day moving average, the case for a continued advance stays alive. A decisive break below it would likely hand the narrative back to fundamental worries about study risk and widen the gap to the 52-week high of EUR 105.80. The next concrete corporate date is the shareholder vote on KPMG's appointment for fiscal 2027 at the annual general meeting, which would close out the planned governance adjustment. The real driver of the broader trend, however, will come from clinical updates, above all the next round of data on Gotistobart.
Ad
BioNTech Stock: New Analysis - 30 September
Fresh BioNTech information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
